摘要
乙型肝炎病毒(HBV)感染是导致我国肝细胞癌(HCC)的最主要原因,长期有效的抗病毒治疗可以明显降低HCC的发生。强效、高耐药基因屏障核背(酸)类似物(NAs)包括恩替卡韦和替诺福韦在临床上广泛使用以来,慢性乙型肝炎患者血清中HBV DNA检测不出率超过85%?95%,但少数患者仍然可以发生HCC。现将对NAs治疗的时机和选择NAs的种类在预防和降低HCC发生率上是否不同等问题做一综述。
Hepatitis B virus(HBV)infection is a leading cause of hepatocellular carcinoma(HCC)in China.The occurrence of HCC can significantly be reduced with effective long-term antiviral treatment.Since the widespread clinical use of nucleos(t)ide analogues,such as entecavir and tenofovir that has a strong potency and high genetic barrier to resistance;the detection rate of HBV DNA in serum of patients with chronic hepatitis B is no more than 85%?95%,but HCC can still occur in a small number of patients.This article will review whether the timing and selection of NAs treatment differ to prevent and reduce the incidence of HCC.
作者
韩超
赖苹苹
窦晓光
Han Chao;Lai Pingping;Dou Xiaoguang(Department ofInfectious Disease,Shengjing Hospital of China Medical University,Shenyang 110022,China)
出处
《中华肝脏病杂志》
CAS
CSCD
北大核心
2019年第11期827-830,共4页
Chinese Journal of Hepatology
基金
“十三五”国家科技重大专项课题(2017ZX10201201,2017ZX10202202)
盛京自由研究者基金(2011-02)。
关键词
癌
肝细胞
肝炎病毒
乙型
核苷(酸)类似物
Carcinoma,hepatocellular
Hepatitis B virus
Nucleos(t)ide analogues
